Gapping up
In reaction to strong earnings/guidance:
- HA +5.1%, FBR +2.6%, ORIT +2.5%, SGRY +2.3%, (Surgery Partners CFO Teresa Sparks is stepping down to pursue other opportunities; co also reaffirmed guidance at the upper half of the range for 2017 revs and Adj. EBITDA ), REV +1.8%, (Fabian Garcia steps down as President and CEO ), PHM +0.9%
M&A news:
- CALD +10.9% (to be acquired by SAP for $36.00 per share)
Other news:
- IMMY +47.6% (Imprimis Pharmaceuticals now making available two glaucoma drugs on FDA's drug shortage list), CRBP +11.9% (Corbus Pharma reaches agreement w/ the FDA regarding the design of its next study of lenabasum in the treatment of cystic fibrosis ), PTI +8.8% (still checking), GNBC +6.4% (to join S&P SmallCap 600), EXTR +6.2% (to join S&P SmallCap 600), GERN +6% (continued strength), DFFN +4.3% (doses the first patient in the Phase 3 clinical trial with trans sodium crocetinate in patients with newly-diagnosed inoperable glioblastoma multiforme), AR +4.1% (to evaluate various potential measures to address the discount in trading value of Antero's stock relative to some of the premier U.S. large capitalization upstream independents ), SMRT +4.1% (assembles team to improve performance and explore strategic alternatives ), PMT +4% (to join S&P SmallCap 600)
Analyst comments:
- GSS +8.7% (initiated with a Outperform at National Bank Financial)
- JBLU +1.5% (upgraded to Overweight from Neutral at JP Morgan)
- UAL +1.4% (upgraded to Overweight from Underweight at JP Morgan)